New drug combo shows promise for tough breast cancer
Disease control
Completed
This study tested a combination of two drugs, ladiratuzumab vedotin (LV) and pembrolizumab, in 185 people with advanced triple-negative breast cancer that had spread. The main goals were to check for side effects and see if the drugs could shrink tumors. The trial found that the …
Phase: PHASE1, PHASE2 • Sponsor: Seagen Inc. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC